STLN
Starling Oncology, Inc.- Healthcare
- Medical - Care Facilities
- $362M market cap
Forecast run · Nov 9, 2026Upside rank 471 of 3,187
Model Signal
ForecastQ Daily Probabilities
52.4%
47.9%
73.2%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$3.62
Price target$9.00
Implied move+148.6%
Analysts4
ForecastQ Portfolios
STLN is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.